PREDICT: Prostate is a new model to predict survival and guide treatment decisions in men with
non-metastatic prostate cancer.
For many years ‘PREDICT’ has been used to guide treatment decisions in breast cancer. It’s website is accessed over 20,000 times a month, with multi-disciplinary teams around the world regularly using the model.
Now, a team of experts across the University of Cambridge have developed a prostate version of PREDICT which shows great promise in informing treatment decisions for men with non-metastatic prostate cancer. Listed below are some key features of the model.
- 10 and 15-year personalised survival estimates
- Prostate cancer mortality contextualised against other mortality
- Potential treatment benefit presented
- Developed using established methodology
- Derived from high quality data from >10,000 UK men
- Validated in UK and Singaporean cohorts
- Good calibration and discrimination
- Multiple graphical styles
- User-orientated interface
- Standardised and unbiased presentation
- Free web-based tool available soon
PREDICT: Prostate has been funded by research grants from The Evelyn Trust and The Urology Foundation. It is the result of longstanding collaborations between the University Department of Public Health (Prof Pharoah) and The Academic Urology Group in the University Department of Surgery (Mr V Gnanapragasam). Web-development and design has been enabled through collaboration with the Winton Centre for Risk and Evidence Communication.
For further information or queries about PREDICT: Prostate, please do not hesitate to get in touch:
Project Lead : Mr David Thurtle firstname.lastname@example.org
Chief Investigator : Mr Vincent Gnanapragasam email@example.com